公开(公告)号：US20240285655A1

公开(公告)日：2024-08-29

申请号：US18586450

申请日：2024-02-24

Applicant: PKZ, LLC

Inventor： J. Phillip Kennedy ,  Karyemaître Aliffe

IPC: A61K31/00 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/167 ,  A61K31/20 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4706 ,  A61K31/593 ,  A61K31/704 ,  A61K33/06 ,  A61K35/10 ,  A61K36/185 ,  A61K38/40 ,  A61K38/48

CPC classification number: A61K31/658 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/167 ,  A61K31/20 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4706 ,  A61K31/593 ,  A61K31/704 ,  A61K33/06 ,  A61K35/10 ,  A61K36/185 ,  A61K38/40 ,  A61K38/482

Abstract: Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

公开(公告)号：US11786564B2

公开(公告)日：2023-10-17

申请号：US17714205

申请日：2022-04-06

Applicant: Uute Scientific Oy

Inventor： Aki Sinkkonen ,  Mira Grönroos ,  Heikki Hyöty ,  Olli-Heikki Laitinen ,  Noora Nurminen ,  Sami Oikarinen

IPC: A61K35/02 ,  A61K35/742 ,  A61K8/96 ,  A61K8/99 ,  A61K9/00 ,  A61K35/10 ,  A61K35/747 ,  A61K35/00 ,  A61K35/12

CPC classification number: A61K35/742 ,  A61K8/965 ,  A61K8/99 ,  A61K9/0014 ,  A61K35/10 ,  A61K35/747 ,  A61K2035/115 ,  A61K2035/122

Abstract: The invention discloses an immunomodulatory composition comprising non-culturable bacteria, a method of production and an article and an apparatus for its use and administration.

公开(公告)号：US20180250250A1

公开(公告)日：2018-09-06

申请号：US15812855

申请日：2017-11-14

Applicant: OMNI BIOCEUTICAL INNOVATIONS, INC.

Inventor： Gary W. Black ,  Jane Christensen ,  Farhan Taghizadeh

IPC: A61K31/194 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K31/194 ,  A61K8/36 ,  A61K8/64 ,  A61K8/965 ,  A61K9/0014 ,  A61K31/352 ,  A61K35/10 ,  A61K45/06 ,  A61K2800/91 ,  A61K2800/92 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2300/00 ,  A61K38/18 ,  A61K38/06

Abstract: Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

公开(公告)号：US20170319475A1

公开(公告)日：2017-11-09

申请号：US14901060

申请日：2015-05-29

Applicant: Darong LIU

Inventor： Darong LIU

IPC: A61K9/00 ,  A61K36/489 ,  A61K36/236 ,  A61K36/32 ,  A61K36/58 ,  A61K9/08 ,  A61K36/00

CPC classification number: A61K9/0053 ,  A61K9/0095 ,  A61K9/08 ,  A61K33/06 ,  A61K35/10 ,  A61K35/36 ,  A61K36/00 ,  A61K36/11 ,  A61K36/23 ,  A61K36/232 ,  A61K36/234 ,  A61K36/236 ,  A61K36/24 ,  A61K36/32 ,  A61K36/324 ,  A61K36/40 ,  A61K36/46 ,  A61K36/481 ,  A61K36/484 ,  A61K36/489 ,  A61K36/58 ,  A61K36/605 ,  A61K36/65 ,  A61K36/71 ,  A61K36/716 ,  A61K36/718 ,  A61K36/725 ,  A61K36/738 ,  A61K36/746 ,  A61K36/75 ,  A61K36/756 ,  A61K36/815 ,  A61K36/899 ,  A61K36/90 ,  A61K36/904 ,  A61K2300/00

Abstract: The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.

公开(公告)号：US08894993B2

公开(公告)日：2014-11-25

申请号：US11881630

申请日：2007-07-27

Applicant: Shibnath Ghosal

Inventor： Shibnath Ghosal

IPC: A61K38/43 ,  A61K38/54 ,  A61K31/122 ,  A23L1/30 ,  A23L2/52 ,  A61K8/34 ,  A61K8/44 ,  A61K31/37 ,  A61K35/10 ,  A61Q19/08 ,  A61Q17/04

CPC classification number: A61K31/122 ,  A23L2/52 ,  A23L33/10 ,  A61K8/347 ,  A61K8/442 ,  A61K31/37 ,  A61K35/10 ,  A61Q17/04 ,  A61Q19/08 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.

Abstract translation: 本发明涉及包含辅酶Q10（CoQ10），还原的CoQ10或其混合物和含氧二苯并-α-吡喃酮或其氨基酰基酯的药物或兽医或营养或个人护理组合物。 本发明的组合物能够支持和/或提供治疗患有风险和/或治疗能力代谢功能障碍，特别是针对线粒体疾病的个体。

公开(公告)号：US5486538A

公开(公告)日：1996-01-23

申请号：US298419

申请日：1994-08-29

Applicant: Bernhard Seubert ,  Anton F. Haase

Inventor： Bernhard Seubert ,  Anton F. Haase

IPC: A61K35/10 ,  C08H99/00 ,  A61K31/28 ,  C07F1/12 ,  C07F15/00

CPC classification number: C08H99/00 ,  A61K35/10

Abstract: A precious metal salt of a low molecular humic acid containing 1 to 5% by weight of the precious metal processes for their preparation and a method of stabilizing alkali metal humate and their medical uses.

Abstract translation: 含有1至5重量％贵金属制备方法的低分子腐殖酸的贵金属盐以及稳定碱金属腐殖酸盐及其医疗用途的方法。

公开(公告)号：US20160296596A1

公开(公告)日：2016-10-13

申请号：US15187513

申请日：2016-06-20

Applicant: PROTECTIMMUN GMBH ,  FORSCHUNGSZENTRUM BORSTEL

Inventor： Marcus Peters ,  Marion Kauth ,  Albrecht Bufe ,  Otto Holst

IPC: A61K38/16 ,  A61K39/39 ,  A61K36/899 ,  A61K31/715 ,  A61K35/744 ,  A61K35/10

CPC classification number: A61K38/168 ,  A61K31/715 ,  A61K35/10 ,  A61K35/74 ,  A61K35/744 ,  A61K36/899 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2300/00

Abstract: A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.

Abstract translation: 预防性抗过敏组合物包括至少一种阿拉伯半乳聚糖或阿拉伯半乳聚糖蛋白。 从草中分离阿拉伯半乳聚糖或阿拉伯半乳聚糖蛋白质，或者其结构排列对应于可从草中分离的阿拉伯半乳聚糖。

公开(公告)号：US20160228469A1

公开(公告)日：2016-08-11

申请号：US15055418

申请日：2016-02-26

Applicant: BioCardia, Inc.

Inventor： Didier Rouy ,  Peter A. Atlman ,  Benjamin Koziner

IPC: A61K35/28 ,  C12N5/0775 ,  A61K9/00

CPC classification number: C12N5/0663 ,  A61K9/0019 ,  A61K35/00 ,  A61K35/10 ,  A61K35/28 ,  A61K2035/124 ,  C12N2500/84 ,  C12N2502/11 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

Abstract translation: 用于扩展可用于临床环境的自体培养基中自体骨髓衍生的间充质细胞的方法，以及将来作为患者服务进行这种扩展的商业方法。 一种在自体培养基中扩增源于自体骨髓的间充质细胞的方法，包括用于自体细胞治疗的诊断试剂盒，以确定患者是否将对自体细胞疗法响应治疗疾病，其中所述试剂盒包含用于 检测包含至少两个分离的DNA分子的基因和蛋白质表达，其中每个分离的DNA分子检测在旨在成为自体细胞治疗来源的患者组织中差异表达的基因的表达。

公开(公告)号：US09375444B2

公开(公告)日：2016-06-28

申请号：US14059180

申请日：2013-10-21

Applicant: PROTECTIMMUN GMBH ,  FORSCHUNGSZENTRUM BORSTEL

Inventor： Marcus Peters ,  Marion Kauth ,  Albrecht Bufe ,  Otto Holst

IPC: A61K31/715 ,  A61K36/899 ,  A61K35/74 ,  A61K35/10 ,  A61K35/744 ,  A61K38/16

CPC classification number: A61K38/168 ,  A61K31/715 ,  A61K35/10 ,  A61K35/74 ,  A61K35/744 ,  A61K36/899 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2300/00

Abstract: A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.

Abstract translation: 预防性抗过敏组合物包括至少一种阿拉伯半乳聚糖或阿拉伯半乳聚糖蛋白。 从草中分离阿拉伯半乳聚糖或阿拉伯半乳聚糖蛋白质，或者其结构排列对应于可从草中分离的阿拉伯半乳聚糖。

公开(公告)号：US20150030558A1

公开(公告)日：2015-01-29

申请号：US14381600

申请日：2013-02-26

Applicant: Syrinx ZA Intenational Limited

Inventor： Rupert Stephen Jude Bevan ,  Anthony Thomas Maleedy ,  Melinda Miriam Coss

IPC: A61K35/02 ,  A61K8/96 ,  A61Q5/02 ,  A61K36/185

CPC classification number: A61K35/02 ,  A61K8/965 ,  A61K35/10 ,  A61K36/185 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q19/00 ,  A61Q19/007 ,  A61Q19/10

Abstract: The present disclosure relates to compositions. More particularly, the present disclosure relates to skincare composition. The present disclosure also relates to methods of forming extracts for inclusion in skincare compositions.

Abstract translation: 本公开涉及组合物。 更具体地，本公开涉及护肤组合物。 本公开还涉及形成用于包含在护肤组合物中的提取物的方法。